ET
KRYS icon

Entropy Technologies’s Krystal Biotech KRYS Stock Holding History

Entropy Technologies’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,200
Closed -$568K – 1100
2026
Q1 		$568K Sell
2,200
-303
-12% -$80.6K 0.03% 558
2025
Q4 		$617K Buy
+2,503
New +$527K 0.03% 505
2025
Q2 		– Sell
-2,300
Closed -$415K – 914
2025
Q1 		$415K Sell
2,300
-1,200
-34% -$202K 0.04% 471
2024
Q4 		$548K Buy
+3,500
New +$621K 0.06% 414

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Entropy Technologies's KRYS Position: Q2 2026 in Review

Entropy Technologies sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 2,200 shares — an estimated $568K sold.

Entropy Technologies first reported a position in KRYS in Q4 2024 and held it in 4 quarters. The position peaked at $617K in Q4 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Entropy Technologies reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Entropy Technologies sold 2,200 Krystal Biotech shares in Q2 2026, an estimated $568K.
  • Entropy Technologies first reported a position in Krystal Biotech in Q4 2024 and held it in 4 quarters.
  • Entropy Technologies's Krystal Biotech position peaked at $617K in Q4 2025.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Entropy Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.